Date: March 31, 2025, 10:36 A.M.
Location: Moderated Poster Theater 7
PROGNOSTIC IMPLICATIONS OF PLATELET FCɣRIIA DURING THE FIRST YEAR AFTER MYOCARDIAL INFARCTION
Read More
With the addition of SBG injections, the West Palm Beach integrative health clinic offers a new option to individuals looking for relief from chronic pain, trauma disorder, and other ailments
Read More
Education event for occupational and environmental medicine physicians will cover biomechanics, research and clinical indications for use of long-duration ultrasound treatment for soft-tissue injury healing.
Read MoreThe closing of the business combination with PowerUp Acquisition Corp. creates Nasdaq-listed biopharmaceutical company dedicated to developing breakthrough innovations in FDA approved drugs, nutraceuticals, and supplements
Aspire has multiple product candidates in key areas of medical needs such as a fast-acting aspirin product for cardiology emergencies and pain management, a proprietary Viagra/Cialis combination product, various bi-hormonal drugs such as testosterone, estrogen, weight loss, anti-seizure, and thyroid drugs. Supplements such as pre-workout and melatonin are already being developed using Aspire's proprietary sublingual delivery system.
Aspire Biopharma Holdings, Inc. ("Aspire Biopharma") is scheduled to begin trading on Nasdaq on February 20, 2025 under the ticker symbol "ASBP".
Read MoreFourth Quarter Highlights
Per Class B share(3): $1.02 adjusted basic earnings up 5.2%; $1.01 basic earnings up 359.1%; $0.54 goodwill impairment loss in 2023 basic earnings; currency translation negative $0.01 per share
Sales increased 9.0% on 6.8% organic growth, 1.4% acquisition growth and 0.8% positive currency translation
CCL, Checkpoint and Innovia posted organic sales growth of 5.4%, 13.3%, and 20.2%, respectively, partly offset by an organic decline for Avery of 2.0%
Operating income(1) improved 5.1%, with a 14.8% operating margin(1) down 50 bps
2024 Highlights
Per Class B share(3): $4.32 adjusted basic earnings up 14.9%; $4.73 basic earnings up 58.2%; $0.44 revaluation gain included in 2024 basic earnings and $0.54 goodwill impairment loss in 2023 basic earnings; currency translation negative $0.02 per share
Sales increased 9.0% on 6.1% organic growth, 2.3% acquisition growth and 0.6% positive currency translation
Operating income(1) improved 13.0%, with a 15.8% operating margin(1) up 60 bps